We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+74.46%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$117M
AUM Growth
+$41.5M
Cap. Flow
+$2.62M
Cap. Flow %
2.24%
Top 10 Hldgs %
97.29%
Holding
16
New
1
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$3.02M
2
EVOK
Evoke Pharma
EVOK
+$134K

Top Sells

Rank Stock Value
1
ARCT icon
Arcturus Therapeutics
ARCT
+$432K
2
SMMT icon
Summit Therapeutics
SMMT
+$106K

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
1
Abeona Therapeutics
ABEO
$345M
$40.2M 34.4%
94,391
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$30.1M 25.78%
807,224
– –
CRBP icon
3
Corbus Pharmaceuticals
CRBP
$170M
$26.7M 22.86%
124,631
– –
NTBL
4
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$5.25M 4.49%
24,589
– –
AVXL icon
5
Anavex Life Sciences
AVXL
$222M
$3M 2.56%
724,205
– –
KRYS icon
6
Krystal Biotech
KRYS
$9.88B
$2.99M 2.56%
+300,000
New +$3.02M
AMPE
7
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$1.61M 1.38%
8,652
– –
KERX
8
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.42M 1.21%
200,000
– –
VNRX icon
9
VolitionRx Ltd
VNRX
$12M
$1.24M 1.06%
23,077
– –
SMMT icon
10
Summit Therapeutics
SMMT
$10.6B
$1.15M 0.99%
91,800
-8,200
-8% -$106K
ALDX icon
11
Aldeyra Therapeutics
ALDX
$91.7M
$893K 0.76%
124,096
– –
ARCT icon
12
Arcturus Therapeutics
ARCT
$157M
$812K 0.69%
114,864
-57,350
-33% -$432K
EVOK
13
DELISTED
Evoke Pharma
EVOK
$752K 0.64%
1,563
+348
+29% +$134K
LSTA icon
14
Lisata Therapeutics
LSTA
$15.2M
$422K 0.36%
7,864
– –
ADXSW
15
DELISTED
Advaxis Inc Warrants
ADXSW
$191K 0.16%
112,500
– –
LPCN icon
16
Lipocine
LPCN
$17.1M
$99K 0.08%
1,471
– –

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Knoll Capital Management held 16 positions worth $117M, up 55% from $75.4M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Knoll Capital Management's Q3 2017 filing shows 1 new, 1 increased and 2 reduced positions. Its largest new stake was Krystal Biotech: 300,000 shares worth $2.99M. The largest sale was Arcturus Therapeutics, an estimated $432K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Knoll Capital Management's largest Q3 2017 buy was Krystal Biotech: 300,000 shares worth $2.99M.
  • Knoll Capital Management added most to Evoke Pharma in Q3 2017, an estimated $134K increase.
  • Knoll Capital Management's biggest Q3 2017 reduction was Arcturus Therapeutics, cutting an estimated $432K.
  • Knoll Capital Management's ten largest holdings make up 97% of its $117M portfolio in Q3 2017.
  • Knoll Capital Management opened 1 new position and closed 0 in Q3 2017.
  • Knoll Capital Management's portfolio value rose 55% quarter-over-quarter to $117M.

Based on Knoll Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.